Browsing by Author "Corbalán Herreros, Ramón"
Now showing 1 - 20 of 49
Results Per Page
Sort Options
- ItemAsociación entre strain y strain rate auricular izquierdo evaluado por speckle tracking y fibrilación auricular post cirugía de revascularización miocárdica(2011) Gabrielli, Luigi; Córdova, S.; Enríquez, A.; Mc-Nab Martin, Paul Andrew; Verdejo Pinochet, Hugo; Godoy, I.; Corbalán Herreros, RamónIntroducción: La fibrilación auricular (FA) es la arritmia más común post cirugía de revascularización miocárdica (CRM) y está asociada a dilatación y disfunción auricular izquierda (AI). El strain y strain rate global longitudinal AI determinado por speckle tracking constituyen herramientas novedosas en la evaluación de la función AI. Objetivo: evaluar el strain y strain rate global longitudinal AI en pacientes con enfermedad coronaria con indicación de CRM y su relación con el desarrollo de FA post operatoria. Métodos: se incluyeron pacientes consecutivos con indicación de CRM, en ritmo sinusal con fracción de eyección > 50%. Se registraron características clínicas y ecocardiográficas con evaluación del strain AI: onda s (LASs) y strain rate: onda a (LASRa), onda s (LASRs) por speckle tracking (pre-cirugía). Se evaluó la ocurrencia de FA en el período post operatorio (una semana) mediante monitorización electrocardiografía continua. Se utilizó t-Student, chi-cuadrado y regresión logística múltiple. Resultados: Se incluyeron 70 pacientes, 26% presentaron FA. LASs, LASRr y LASRa estaban significativamente disminuidos en los pacientes que desarrollaron FA post CRM, LASs (10 ± 1,1 vs 24 ± 1,2%, p < 0,001), LASRa (- 0,6 ± 0,1 vs - 1,8 ± 0,12, p < 0,001) LASRs (0,6 ± 0,007 vs 1,2 ± 0,008, p < 0,001). Los pre-dictores independientes de FA fueron: LASRs OR: 6,1 IC 95% (1,3-15,2); LASRa OR: 2,4 IC 95% (1,1-19,6); volumen AI OR: 4,67 IC 95% (1,5-19,2) y edad > 65 años OR: 2,31 IC 95% (1,1-15,8). Conclusiones: LASs, LASRs y LASRa están disminudos en pacientes que desarrollan FA post CRM y LASRs, LASRa fueron predictores independientes de ésta.
- ItemAssessment of Left Atrial Function in Hypertrophic Cardiomyopathy and Athlete's Heart: A Left Atrial Myocardial Deformation Study(2012) Gabrielli, Luigi; Enríquez, Andrés; Córdova Alvestegui, Samuel Edmundo; Yáñez, Fernando; Godoy J., Iván; Corbalán Herreros, Ramón
- ItemAtherothrombotic Disease, Traditional Risk Factors, and 4-Year Mortality in a Latin American Population: The REACH Registry(2012) Cantú Brito, Carlos; Chiquete, Erwin; Ruiz Sandoval, José L.; Gaxiola, Efraín|Albuquerque, |Denilson C.; Corbalán Herreros, Ramón; Ramos, Alma; Bhatt, Deepak L. L.; Steg, Gabriel
- ItemAtherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction(2016) Bohula, Erin A.; Bonaca, Marc P.; Braunwald, Eugene; Aylward, Philip E.; Corbalán Herreros, Ramón; De Ferrari, Gaetano, M.; Ping He; Lewis, Basil S.; Merlini, Piera A.; Murphy, Sabina A.; Sabatine, Marc S.; Scirica, Benjamin M.; Morrow, David A.
- ItemAtrial Function Assessed by Speckle Tracking Echocardiography Is a Good Predictor of Postoperative Atrial Fibrillation in Elderly Patients(2016) Castro Gálvez, Pablo Federico; Lavandero, S.; Gabrielli, Luigi; Corbalán Herreros, Ramón; Verdejo Pinochet, Hugo; Becerra, E.; Zalaquett Sepúlveda, Ricardo; Del Campo, Andrea; Garcia, L.; Troncoso Pino, Rodrigo; Chiong, M.; Marin, A.
- ItemBiomarcadores coronarios y evolución clínica alejada en pacientes con síndromes coronarios agudos sin elevación del segmento ST(2005) Baeza Vergara, Ricardo Gabriel; Corbalán Herreros, Ramón; Castro Gálvez, Pablo Federico; Acevedo B., Mónica; Quiroga G., Teresa; Viviani García, PaolaThe use of new biomarkers improved risk stratification for patients with acute coronary syndromes (ACS). Aim: To evaluate the relationship between multiple biomarkers and long-term clinical outcome in ACS without ST segment elevation. Patients and Methods: Consecutive patients presenting with suspected ACS were studied. On admission to the emergency room, serum was obtained to determine highly sensitive C reactive protein (hsCRP), erythrocyte sedimentation rate (ESR), lipoprotein (a) (LPa) and soluble P selectin (sPS). Clinical endpoints were mortality and a composite endpoint of major adverse cardiovascular events (MACE) including death, re-infarction, and angina. Results: Seventy patients, aged 63±13 years, 54 males, were studied. Final diagnosis was unstable angina in 71% and non-ST-segment elevation myocardial infarction in 29%. MACE and mortality rate were 17% and 5.8%, respectively. We found higher plasma levels of hsCRP, ESR and Lp(a) in patients with MACE (p=0.032, p=0.015 and p=0.010, respectively). Plasma levels of hsCRP and ESR were also higher in patients who died during the follow up (p=0.002 y p=0.045, respectively). Conclusion: Plasma levels of inflammatory markers and atherosclerosis biomarkers are associated with a worse long-term clinical outcome in ACS without ST segment elevation. The inclusion of these biomarkers in the routine blood test on admission, could improve risk stratification of patients with ACS in the future (Rev Méd Chile 2005; 133: 1275-93).
- ItemCHANGES IN BETA-ADRENERGIC RECEPTORS OF RAT-HEART AND ADIPOCYTES DURING VOLUME-OVERLOAD INDUCED CARDIAC-HYPERTROPHY(1993) Cartagena, G.; Sapag-Hagar, M.; Jalil Milad, Jorge; Tapia Pinto, Verónica Mildred; Guarda, E.; Foncea Ávila, Rocío Eugenia; Corbalán Herreros, Ramón; Ebensperger González, Roberto Alejandro; Lavandero, S.
- ItemConcomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization : insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial(2015) Nicolau, Jose Carlos; Bhatt, Deepak L.; Roe, Matthew T.; Lokhnygina, Yuliya; Neely, Benjamin; Corbalán Herreros, Ramón; Leiva-Pons, José L.; Martinez, Felipe; Goodman, Shaun G.; Winters, Kenneth J.; Verheugt, Freek W.A.; Armstrong, Paul W.; White, Harvey D.; Fox, Keith A. A.; Prabhakaran, Dorairaj; Ohman, E. Magnus
- ItemDarapladib for preventing ischemic events in stable coronary heart disease(2014) White, H.; Held, C.; Stewart, R.; Tarka, E.; Brown, R.; Davies, R.; Budaj, A.; Harrington, R.; Steg, P.; Corbalán Herreros, Ramón
- ItemDevelopment of an international standard set of outcome measures for patients with atrial fibrillation : a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group(2020) Seligman, W. H.; Das Gupta, Z.; Jobi Odeneye, A. O.; Arbelo, E.; Banerjee, A.; Bollmann, A.; Caffrey Armstrong, B.; Cehic, D. A.; Corbalán Herreros, Ramón; Collins, M.; Dandamudi, G.; Dorairaj, P.; Fay, M.; Van Gelder, I. C.; Goto, S.; Granger, C. B.; Gyorgy, B.; Healey, J. S.; Hendriks, J. M.; Hills, M. T.; Hobbs, F. D. R.; Huisman, M. V.; Koplan, K. E.; Lane, D. A.; Lewis, W. R.; Lobban, T.; Steinberg, B. A.; McLeod, C. J.; Moseley, S.; Timmis, A.; Yutao, G.; Camm, A. J.
- ItemDisagreements between central clinical events committee and site investigator assessments of myocardial infarction end-points in an international clinical trial : review of the PURSUIT study(2001) Corbalán Herreros, Ramón; Mahaffey, Kenneth W.; Harrington, Robert A.; Akkerhuis, Martijn.; Kleiman, Neal S.; Berdan, Lisa G.; Crenshaw, Brian S.; Tardiff, Barbara E.; Granger, Christopher B.; DeJong, Ingrid.Abstract Background Limited information has been published regarding how specific processes for event adjudication can affect event rates in trials. We reviewed nonfatal myocardial infarctions (MIs) reported by site investigators in the international Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin (Eptifibatide) Therapy (PURSUIT) trial and those adjudicated by a central clinical events committee (CEC) to determine the reasons for differences in event rates. Methods The PURSUIT trial randomised 10,948 patients with acute coronary syndromes to receive eptifibatide or placebo. The primary end-point was death or post-enrolment MI at 30 days as assessed by the CEC; this end-point was also constructed using site-reported events. The CEC identified suspected MIs by systematic review of clinical, cardiac enzyme, and electrocardiographic data. Results The CEC identified 5005 (46%) suspected events, of which 1415 (28%) were adjudicated as MI. The site investigator and CEC assessments of whether a MI had occurred disagreed in 983 (20%) of the 5005 patients with suspected MI, mostly reflecting site misclassification of post-enrolment MIs (as enrolment MIs) or underreported periprocedural MIs. Patients for whom the CEC and site investigator agreed that no end-point MI had occurred had the lowest mortality at 30 days and between 30 days and 6 months, and those with agreement that a MI had occurred had the highest mortality. Conclusion CEC adjudication provides a standard, systematic, independent, and unbiased assessment of end-points, particularly for trials that span geographic regions and clinical practice settings. Understanding the review process and reasons for disagreement between CEC and site investigator assessments of MI is important to design future trials and interpret event rates between trials.
- ItemDual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY. ACS. Trial(2016) Jackson, L.; Piccini, J.; Cyr, D.; Roe, M.; Neely, M.; Martínez, F.; Luscher, T.; Lopes, R.; Winters, K.; Corbalán Herreros, Ramón; White, H.; Armstrong, P.; Fox, K.; Prabhakaran, D.; Bhatt, D.; Ohman, E.
- ItemEdoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation : The ENGAGE AF-TIMI 48 Trial(2018) Corbalán Herreros, Ramón; Nicolau, José Carlos; López Sendon, José; García Castillo, Armando; Botero, Rodrigo; Sotomora, Gustavo; Horna, Manuel; Ruff, Christian T.; Hamershock, Rose A.; Grip, Laura T.
- ItemEffect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61) : a randomised, placebo-controlled trial(2018) Bohula, Erin A.; Scirica, Benjamín M.; Inzucchi, Silvio E.; McGuire, Darren K.; Keech, Anthony C.; Smith, Steven R.; Kanevsky, Estella; Murphy, Sabina A.; Leiter, Lawrence A.; Corbalán Herreros, Ramón; Dwyer, Jamie P.; Hamm, Christian
- ItemEffect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients(2016) Chin, C.; Boden, W.; Roe, M.; Neely, B.; Neely, M.; Leiva, J.; Corbalán Herreros, Ramón; Gottlieb, S.; Dalby, A.; Armstrong, P.; Prabhakaran, D.; Fox, K.; White, H.; Ohman, E.; Winters, K.; Schiele, F.
- ItemEfficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation : insights from the ENGAGE AF-TIMI 48 trial(2020) Nicolau, A. M.; Corbalán Herreros, Ramón; Nicolau, J. C.; Ruff, C. T.; Zierhut, W.; Kerschnitzki, M.; Duris, T.; Juul-Moller, S.; Voitk, J.; Trevisan, M.; Nordio, F.; Antman, E. M.; Giugliano, R. P.
- ItemEfficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI. 54 trial(2016) Magnani, G.; Storey, R.; Steg, G.; Bhatt, D.; Kuder, J.; Im, K.; Aylward, P.; Ardissino, D.; Isaza, D.; Corbalán Herreros, Ramón; Dellborg, D.; Medina, F.; Braunwald, E.; Sabatine, M.; Bonaca, M.; Jensen, E.
- ItemEfficacy and safety of vorapaxar with and without a thienopyridine for secondary prevention in patients with previous myocardial infarction and no history of stroke or transient ischemic attack : Results from TRA 2°P-TIMI 50(2015) Bohula, E.; Aylward, P.; Bonaca, M.; Corbalán Herreros, Ramón; Kiss, R.; Murphy, S.; Scirica, B.; White, H.; Braunwald, E.; Morrow, D.
- ItemEficacia y seguridad del tratamiento anticoagulante oral con antagonistas de vitamina K en pacientes con prótesis valvulares cardíacas(2014) Marín, A.; Neira, V.; Aizman, Andrés; Paredes, A.; Palma, S.; Ruiz, M.; Revello, J.; Zvaighaft, S.; Cea, C.; Corbalán Herreros, RamónIntroducción: Los pacientes con válvulas mecánicas cardíacas (VMC) representan una proporción significativa del total de pacientes que requieren anticoagulación. Sin embargo, hay pocos estudios que comparen la efectividad de la anticoagulación con distintos antagonistas de vitamina K (AVK). Objetivo: Comparar la efectividad y seguridad del tratamiento con warfarina y acenocumarol en pacientes con VMC. Métodos: Estudio observacional de pacientes en po-liclínico de anticoagulación UC sometidos a recambio valvular entre los años 2005 y 2013. Se estandarizó las dosis de AVK con software Isaza Hytwin Biostac 2.0. Se evaluaron registros de hemorragia mayor y menor (seguridad) y accidentes vasculares y embolías sistémicas (efectividad). La efectividad se analizó mediante el tiempo en rango terapéutico (TTR) con método de Ro-sendaal. Resultados: Se incluyó 365 pacientes con edad promedio de 64,1 ± 13,2 años, 53,9% de sexo femenino. El seguimiento promedio fue de 33,3 ± 18 meses; La mortalidad registrada fue 2,1%. El promedio de TTR fue 68 ± 13,3% (recambio aórtico TTR 66,1 ± 12,6%, recambio mitral TTR 65,8 ± 13,8% y recambio mitro-aórtico TTR 61,2 ± 12%). Acenocumarol presentó un TTR menor que warfarina (65,1 ± 13,1 vs. 71,2 ± 13,6, p = 0,001), sin aumento del riesgo de complicaciones. Conclusión:Aunque warfarina ofrece un mejor perfil de TTR, no existen diferencias significativas en la eficacia o seguridad al compararla con acenocumarol.
- ItemEvaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation(2016) Neira, V.; Corbalán Herreros, Ramón; Pereira Garcés, Jaime Ignacio; Panes Becerra, Olga Teresa; Garayar Pulgar, Bernardita; Aizman, Andrés; Llevaneras, S.; Villarroel del Pino, Luis A.
- «
- 1 (current)
- 2
- 3
- »